ClinicalIntelPulse · Clinical Disease Landscape

import { wrapFetchWithPayment } from "@x402/fetch";
import { privateKeyToAccount } from "viem/accounts";

const account = privateKeyToAccount(process.env.PRIVATE_KEY);
const fetchWithPay = wrapFetchWithPayment(fetch, account);

const res = await fetchWithPay("https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape", {
  method: "GET",
});
const data = await res.json();

curl -X GET \
  "https://clinicalintelpulse.theaslangroupllc.com/api/clinical/disease-landscape?condition=Disease+area+%E2%80%94+e.g.+%22Parkinson+Disease%22+%7C+%22Breast+Cancer%22+%7C+%22NASH%22+%7C+%22Heart+Failure%22+%7C+%22Schizophrenia%22&depth=standard+%7C+deep+%28default%3A+standard%29&lang=en+%7C+es+%7C+fr+%7C+de+%7C+ja+%7C+zh+%7C+ko+%7C+pt+%7C+ar+%7C+hi+%28default%3A+en%29" \
  -H "X-PAYMENT: <signed x402 payment>"

{
  "approved_drugs": [
    {
      "approved": "2024-03",
      "indication": "NASH with moderate-to-advanced fibrosis",
      "mechanism": "THR-β agonist",
      "name": "Resmetirom (Rezdiffra)",
      "sponsor": "Madrigal Pharmaceuticals"
    }
  ],
  "deal_activity": "Highly active M&A space. AstraZeneca acquired Eccogene NASH program ($185M). Roche/Genentech building liver portfolio. Novo Nordisk GLP-1 dominance creating competitive panic.",
  "investment_thesis": "NASH market projected $18-25B by 2030. Resmetirom first approval sets pricing precedent. GLP-1 combination therapy is the likely future standard of care.",
  "key_readouts_next_18m": [
    "NASH-RESOLVE (semaglutide histology 2025)",
    "MAESTRO-NASH (lanifibranor 2025)",
    "ATLAS trial (aldafermin 2026)"
  ],
  "mechanism_landscape": {
    "crowded": [
      "FXR agonists (8 Phase 2/3)",
      "ACC inhibitors (6)",
      "FGF21 analogs (5)"
    ],
    "emerging": [
      "Pan-PPAR agonists",
      "GLP-1/GIP combinations (semaglutide expanding)"
    ],
    "opportunity_gaps": [
      "Cirrhosis reversal agents",
      "Pediatric NAFLD",
      "Combination sequential therapy protocols"
    ]
  },
  "opportunity_score": {
    "max": 100,
    "note": "Validated market with first approval. GLP-1 expansion threatening narrow competitors.",
    "rating": "High Value",
    "score": 78
  },
  "pdufa_calendar": [
    {
      "drug": "Lanifibranor",
      "mechanism": "Pan-PPAR",
      "pdufa_estimate": "2026-Q1",
      "priority_review": false,
      "sponsor": "Inventiva"
    }
  ],
  "pipeline_overview": {
    "approval_recent_12m": 1,
    "approved_drugs": 2,
    "phase2_count": 48,
    "phase3_count": 19,
    "total_active": 67
  },
  "query_summary": {
    "as_of": "2026-06-07",
    "condition": "NASH (Nonalcoholic Steatohepatitis)",
    "depth": "standard"
  },
  "top_phase3_assets": [
    {
      "completion": "2025-Q4",
      "drug": "Semaglutide 2.4mg",
      "mechanism": "GLP-1 RA",
      "nctId": "NCT04858633",
      "significance": "Blockbuster potential — NASH + obesity combined label",
      "sponsor": "Novo Nordisk"
    }
  ]
}